151153 20251017144608.0 doi 10.1021/acsami.1c02338 sideral 124397 ART-2021-124397 eng Beola, L. (orcid)0000-0003-4516-8694 Critical Parameters to Improve Pancreatic Cancer Treatment Using Magnetic Hyperthermia: Field Conditions, Immune Response, and Particle Biodistribution 2021 Access copy available to the general public Unrestricted Magnetic hyperthermia (MH) was used to treat a murine model of pancreatic cancer. This type of cancer is generally characterized by the presence of dense stroma that acts as a barrier for chemotherapeutic treatments. Several alternating magnetic field (AMF) conditions were evaluated using three-dimensional (3D) cell culture models loaded with magnetic nanoparticles (MNPs) to determine which conditions were producing a strong effect on the cell viability. Once the optimal AMF conditions were selected, in vivo experiments were carried out using similar frequency and field amplitude parameters. A marker of the immune response activation, calreticulin (CALR), was evaluated in cells from a xenograft tumor model after the MH treatment. Moreover, the distribution of nanoparticles within the tumor tissue was assessed by histological analysis of tumor sections, observing that the exposure to the alternating magnetic field resulted in the migration of particles toward the inner parts of the tumor. Finally, a relationship between an inadequate body biodistribution of the particles after their intratumoral injection and a significant decrease in the effectiveness of the MH treatment was found. Animals in which most of the particles remained in the tumor area after injection showed higher reductions in the tumor volume growth in comparison with those animals in which part of the particles were found also in the liver and spleen. Therefore, our results point out several factors that should be considered to improve the treatment effectiveness of pancreatic cancer by magnetic hyperthermia. info:eu-repo/grantAgreement/ES/MCIU-AEI-FEDER/BIO2017-84246-C2-1-R info:eu-repo/grantAgreement/EUR/M-ERA.NET/COFUND-MagicCellGene-PCIN-2017-060 info:eu-repo/grantAgreement/ES/MINECO/PGC2018-096016-B-I00 info:eu-repo/semantics/openAccess by https://creativecommons.org/licenses/by/4.0/deed.es 10.383 2021 NANOSCIENCE & NANOTECHNOLOGY 23 / 108 = 0.213 2021 Q1 T1 MATERIALS SCIENCE, MULTIDISCIPLINARY 49 / 344 = 0.142 2021 Q1 T1 2.143 2021 Medicine (miscellaneous) 2021 Q1 Materials Science (miscellaneous) 2021 Q1 14.4 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Grazu, V. (orcid)0000-0001-6170-4237 Fernandez-Afonso, Y. (orcid)0000-0002-0970-1917 Fratila, R.M. (orcid)0000-0001-5559-8757 De Las Heras, M. Universidad de Zaragoza (orcid)0000-0003-3792-287X De La Fuente, J.M. Gutierrez, L. Universidad de Zaragoza (orcid)0000-0003-2366-3598 Asin, L. 2009 750 Universidad de Zaragoza Dpto. Química Analítica Área Química Analítica 1009 773 Universidad de Zaragoza Dpto. Patología Animal Área Sanidad Animal 13, 11 (2021), 12982–12996 ACS appl. mater. interfaces ACS applied materials & interfaces 1944-8244 6594092 http://zaguan.unizar.es/record/151153/files/texto_completo.pdf Versión publicada 3261109 http://zaguan.unizar.es/record/151153/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:151153 articulos driver 2025-10-17-14:16:11 ARTICLE